The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine

Journal of Hepatology

Volumn 37, Issue 2, 2002, Pages 253-258

  Wolters, Leonieke M M ^a   Hansen, Bettina E ^a   Niesters, Hubert G M ^a   Levi Drummer, Rachel S ^b   Neumann, Avidan U ^b   Schalm, Solko W ^a   De Man, Robert A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Baseline characteristics; Chronic hepatitis B patients; Lamivudine; Viral dynamic parameters

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; VIRUS DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DYNAMICS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; HYPOTHESIS; LINEAR REGRESSION ANALYSIS; LIVER CELL; MALE; MATHEMATICAL MODEL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZATION; VIROLOGY; VIRUS TITRATION; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; LAMIVUDINE; LINEAR MODELS; MALE; MIDDLE AGE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0036022843     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00113-7     Document Type: Article

References (26)

1. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
2. A one-year trial of lamivudine for chronic hepatitis B
3. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
4. Lamivudine as initial treatment for chronic hepatitis B in the United States
5. Dynamics of hepatitis B virus infection in vivo
6. Viral dynamics in hepatitis B virus infection
7. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
8. Bi-phasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
9. Viral dynamics in chronic hepatitis B patients during lamivudine therapy
10. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
11. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
12. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment
13. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
14. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a
15. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations
16. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
17. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
18. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
19. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine
20. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB)
21. Seroconversion after lamivudine treatment is not durable in chronic hepatitis B
22. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
23. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
24. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
25. Clinical pharmacokinetics of lamivudine